Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Purdue Pharma's opioid settlement and dissolution

Purdue Pharma's opioid settlement and dissolution

Rule Changes
By Newzino Staff |

OxyContin maker becomes nonprofit Knoa Pharma after multi-billion dollar settlement and criminal sentence

Today: Purdue dissolves into Knoa Pharma

Overview

OxyContin launched in 1996 with marketing that downplayed addiction risk. Thirty years and hundreds of thousands of overdose deaths later, the company that made it no longer exists. On May 1, 2026, Purdue Pharma was dissolved and substantially all of its assets transferred to Knoa Pharma, a newly formed nonprofit owned by an independent foundation and mandated to supply opioid use disorder treatments and overdose-reversal drugs without maximizing profit.

Why it matters

One of the largest mass-tort cases in U.S. history is closing with a private pharmaceutical empire converted into a public-benefit drugmaker funding addiction treatment.

Key Indicators

$7.4B
Civil settlement
Sackler family and Purdue funds payable to states, localities, tribes, and individual victims over time.
$5.5B
Criminal penalty
Federal sentence imposed April 28, 2026 in the District of New Jersey for the company's role in the opioid epidemic.
~280,000
Prescription opioid overdose deaths
U.S. deaths involving prescription opioids since OxyContin's 1996 launch, per Centers for Disease Control and Prevention data.
6+ years
Bankruptcy duration
Time from Purdue's September 2019 Chapter 11 filing to the May 2026 dissolution.
Nonprofit
Successor structure
Knoa Pharma is owned by an independent foundation and barred from prioritizing profit over public health.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Richard Sackler
Richard Sackler
Released from civil claims by participating creditors under the confirmed plan
 David Sackler
David Sackler
Participating in settlement contributions
 Letitia James
Letitia James
Lead negotiator for state attorneys general coalition
 Sean Lane
Sean Lane
Confirmed final reorganization plan

Organizations Involved

Purdue Pharma
Purdue Pharma
Pharmaceutical company (dissolved)
Dissolved May 1, 2026; assets transferred to Knoa Pharma

Privately held drugmaker controlled by the Sackler family that developed and aggressively marketed OxyContin starting in 1996.
Knoa Pharma
Knoa Pharma
Public-benefit pharmaceutical company
Active; took possession of Purdue assets May 1, 2026

Nonprofit successor to Purdue Pharma, owned by an independent foundation and mandated to supply opioid use disorder treatments and overdose-reversal medicines without maximizing profit.
Sackler family
Sackler family
Owners of Purdue Pharma (former)
Pharmaceutical ownership ended; settlement payments ongoing

The branch of the Sackler family that controlled Purdue for decades is exiting the U.S. pharmaceutical business under the settlement.
Department of Justice
Department of Justice
Federal agency
Secured criminal conviction and sentencing

Federal prosecutor that obtained Purdue's 2020 guilty plea and the April 2026 criminal sentence.

Timeline

  1. Purdue dissolves into Knoa Pharma

    Corporate

    Purdue ceases operations; assets transfer to nonprofit Knoa Pharma owned by an independent foundation.

  2. Criminal sentence imposed

    Legal

    Federal judge in New Jersey sentences Purdue to $5.5 billion criminal penalty, clearing path for dissolution.

  3. Plan confirmed

    Legal

    Bankruptcy court confirms reorganization creating Knoa Pharma and tied to the $7.4 billion settlement.

  4. New framework reached

    Negotiation

    Mediated talks produce a restructured deal with higher Sackler contributions and consent-based releases.

  5. Harrington v. Purdue Pharma decided

    Legal

    Supreme Court rules 5-4 that bankruptcy plans cannot release non-debtors from claims without claimant consent.

  6. Supreme Court stays plan

    Legal

    Justices halt implementation while reviewing whether bankruptcy law allows non-consensual third-party releases.

  7. Sackler contribution increased

    Negotiation

    Holdout states agree to revised plan after Sacklers boost contribution to roughly $6 billion.

  8. First plan confirmed

    Legal

    Bankruptcy court approves a reorganization granting Sacklers releases from civil claims; multiple states appeal.

  9. Federal guilty plea

    Legal

    Purdue pleads guilty to defrauding the United States and to kickback violations as part of an $8.3 billion paper resolution.

  10. Chapter 11 filing

    Legal

    Purdue files for bankruptcy in the Southern District of New York to consolidate thousands of opioid claims.

  11. Mass-tort wave begins

    Legal

    Hundreds of state, county, city, and tribal lawsuits target Purdue and the Sackler family over opioid marketing.

  12. First guilty plea

    Legal

    Purdue Frederick affiliate and three executives plead guilty to misbranding OxyContin; pay $635 million.

  13. OxyContin launches

    Product

    Purdue introduces OxyContin with marketing claiming a less than 1 percent addiction rate when used for pain.

Scenarios

1

Knoa Pharma stabilizes as a model nonprofit drugmaker

Discussed by: State attorneys general supporting the plan; public-health analysts at academic medical centers

Knoa hits its production targets for buprenorphine, naloxone, and related products while generating cash to fund settlement payments on schedule. The structure becomes a reference point for future mass-tort resolutions involving products with ongoing public-health utility, and the Sackler payments arrive in the amounts and timing described in the plan.

2

Sackler payments fall short or stretch out

Discussed by: Bankruptcy law commentators; state officials who opposed earlier plans

Family contributions are paid over many years from assets that include illiquid holdings. If valuations underperform or family members litigate disputed amounts, settlement disbursements to states and victims slow. Communities expecting rapid funding for treatment programs may need to bridge gaps with their own budgets.

3

Non-participating claimants pursue Sacklers individually

Discussed by: Plaintiffs' attorneys; legal academics analyzing post-Harrington precedent

Because the new releases are consent-based, claimants who opted out retain the right to sue Sackler family members directly. A high-profile individual judgment could reopen public debate over the family's wealth and prompt additional settlements outside the bankruptcy framework.

4

Federal or state criminal case targets individual Sacklers

Discussed by: Former federal prosecutors; advocacy groups for opioid victims

Civil releases do not bar criminal prosecution. A new administration or state prosecutor could revisit individual conduct based on internal documents already in the public record. Statute-of-limitations issues and the absence of prior charges make this less likely than civil follow-on litigation.

Historical Context

Tobacco Master Settlement Agreement (1998)

November 1998

What Happened

Forty-six state attorneys general settled with the four largest U.S. tobacco companies for an estimated $206 billion over 25 years, plus restrictions on marketing to minors. The deal followed years of state lawsuits seeking to recover Medicaid costs from smoking-related illness.

Outcome

Short Term

States received annual payments; tobacco advertising on billboards and to youth was sharply curtailed.

Long Term

Funds were often diverted to general budgets rather than smoking cessation, and tobacco companies remained profitable—lessons cited by negotiators pushing for the Knoa nonprofit structure.

Why It's Relevant Today

Like the tobacco deal, the Purdue settlement converts mass-tort exposure into a multi-decade revenue stream for states, with familiar concerns about whether money reaches its intended public-health purpose.

Johns-Manville asbestos bankruptcy (1982)

August 1982

What Happened

Asbestos manufacturer Johns-Manville filed Chapter 11 facing tens of thousands of injury claims. The 1988 reorganization created a trust funded by the company's stock and insurance to pay current and future claimants, and shielded the reorganized company from new asbestos suits.

Outcome

Short Term

Trust began paying claimants at reduced cents-on-the-dollar rates as filings exceeded projections.

Long Term

Established the template—now codified in Section 524(g) of the Bankruptcy Code—for resolving mass torts through dedicated trusts, the structural ancestor of Purdue's settlement vehicle.

Why It's Relevant Today

Manville pioneered using bankruptcy to channel mass claims into a structured payout while keeping useful operations alive—the same logic that produced Knoa Pharma.

A.H. Robins Dalkon Shield bankruptcy (1985)

August 1985

What Happened

Pharmaceutical company A.H. Robins filed Chapter 11 under thousands of injury claims from its Dalkon Shield intrauterine device. A 1988 plan funded a $2.475 billion claimants' trust and was paired with American Home Products' acquisition of the company.

Outcome

Short Term

Trust paid roughly 200,000 claimants over more than a decade.

Long Term

Demonstrated that pharmaceutical mass torts could be resolved through bankruptcy with operational continuity—but also showed disputes over how much insiders should personally contribute, a question that defined the Purdue case.

Why It's Relevant Today

The Dalkon Shield case is the closest pharmaceutical analogue and shaped expectations about owner contributions in product-liability bankruptcies.

Sources

(4)
Purdue Pharma CNBC Oregon Public Broadcasting Fox Business